GnRH Agonist Co-treatment for Prevention of Primary Ovarian Insufficiency in Patients with Hematologic Malignancies Undergoing Chemotherapy / 대한폐경학회지
The Journal of Korean Society of Menopause
;
: 93-100, 2013.
Article
in Korean
| WPRIM
| ID: wpr-227739
ABSTRACT
OBJECTIVES:
The aim of this study was to assess the effect of gonadotropin-releasing hormone (GnRH) agonist co-treatment for gonadal protection in patients with hematologic neoplasms undergoing chemotherapy.METHODS:
Young premenopausal women who were diagnosed with leukemia or lymphoma between March 2010 and February 2012 and undergoing chemotherapy in a university hospital were included in this study.RESULTS:
Twenty-nine patients aged 15.39 years participated in this study. Among the patients, five patients were receiving leuprolide concomitant with chemotherapy, and twenty-four patients were receiving chemotherapy alone. Seventeen patients in the chemotherapy alone group stopped menstrating and were diagnosed with primary ovarian insufficiency (POI) within one year after chemotherapy; and only one patient had POI in the chemotherapy plus leuprolide group, but these differences were not statistically significant (P = 0.054). In the chemotherapy plus leuprolide group, serum anti-mullerian hormone (AMH) levels were significantly lower than basal serum AMH levels (5.57 +/- 0.18 ng/mL) (P < 0.001) after treatment (1.84 +/- 0.22 ng/mL).CONCLUSION:
GnRH agonist may be a promising option for the prevention of POF, but the effectiveness of GnRH agonist is still debatable. A large prospective multi-center trial with adequate follow-up is needed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Leukemia
/
Gonadotropin-Releasing Hormone
/
Leuprolide
/
Primary Ovarian Insufficiency
/
Hematologic Neoplasms
/
Anti-Mullerian Hormone
/
Gonads
/
Lymphoma
Type of study:
Controlled clinical trial
Limits:
Aged
/
Female
/
Humans
Language:
Korean
Journal:
The Journal of Korean Society of Menopause
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS